Header Logo

Connection

HUSSEIN TAWBI to Melanoma

Back to Details
This is a "connection" page, showing publications HUSSEIN TAWBI has written about Melanoma.
HUSSEIN TAWBI
Connection Strength
10.813
Melanoma
  1. Local and Systemic Management Options for Melanoma Brain Metastases. Cancer J. 2024 Mar-Apr 01; 30(2):102-107.
    View in: PubMed
    Score: 0.287
  2. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice. Melanoma Res. 2023 10 01; 33(5):406-416.
    View in: PubMed
    Score: 0.276
  3. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. NEJM Evid. 2023 Apr; 2(4):EVIDoa2200239.
    View in: PubMed
    Score: 0.269
  4. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. J Immunother Cancer. 2023 03; 11(3).
    View in: PubMed
    Score: 0.268
  5. Symptomatic melanoma CNS metastases in the TRICOTEL study - Authors' reply. Lancet Oncol. 2022 11; 23(11):e482.
    View in: PubMed
    Score: 0.262
  6. Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions. Melanoma Res. 2022 12 01; 32(6):393-404.
    View in: PubMed
    Score: 0.261
  7. Current and emerging options for patients with melanoma brain metastases. Clin Adv Hematol Oncol. 2022 Oct; 20(10):619-627.
    View in: PubMed
    Score: 0.260
  8. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2022 09; 23(9):1145-1155.
    View in: PubMed
    Score: 0.257
  9. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.254
  10. Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. Reply. N Engl J Med. 2022 05 12; 386(19):1860-1861.
    View in: PubMed
    Score: 0.253
  11. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma. J Manag Care Spec Pharm. 2022 Mar; 28(3):342-353.
    View in: PubMed
    Score: 0.250
  12. Nivolumab plus ipilimumab in melanoma brain metastases - Authors' reply. Lancet Oncol. 2022 02; 23(2):e54.
    View in: PubMed
    Score: 0.249
  13. Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real-world study. Cancer Med. 2022 01; 11(1):139-150.
    View in: PubMed
    Score: 0.246
  14. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021 12; 22(12):1692-1704.
    View in: PubMed
    Score: 0.245
  15. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 2021 11 02; 23(11):1961-1973.
    View in: PubMed
    Score: 0.244
  16. Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:79-90.
    View in: PubMed
    Score: 0.233
  17. Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.221
  18. "Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis? Clin Cancer Res. 2020 05 01; 26(9):2083-2084.
    View in: PubMed
    Score: 0.218
  19. The standard of care for brain metastases in melanoma. Clin Adv Hematol Oncol. 2020 Jan; 18(1):28-31.
    View in: PubMed
    Score: 0.215
  20. A promising start for checkpoint inhibitors in childhood malignancies. Lancet Oncol. 2020 01; 21(1):13-14.
    View in: PubMed
    Score: 0.214
  21. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer. 2020 02 01; 126(3):523-530.
    View in: PubMed
    Score: 0.212
  22. PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy. Sci Rep. 2019 03 01; 9(1):3309.
    View in: PubMed
    Score: 0.203
  23. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23; 379(8):722-730.
    View in: PubMed
    Score: 0.196
  24. New Era in the Management of Melanoma Brain Metastases. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:741-750.
    View in: PubMed
    Score: 0.192
  25. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017 09 19; 5(1):74.
    View in: PubMed
    Score: 0.184
  26. Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma. Ann Intern Med. 2017 Sep 05; 167(5):361-362.
    View in: PubMed
    Score: 0.182
  27. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. J Immunother Cancer. 2017; 5:45.
    View in: PubMed
    Score: 0.180
  28. Combination therapies for treating metastatic melanoma. Clin Adv Hematol Oncol. 2015 Apr; 13(4):211-4.
    View in: PubMed
    Score: 0.155
  29. Matching wits with melanoma brain metastases: from biology to therapeutics. Clin Cancer Res. 2014 Nov 01; 20(21):5346-8.
    View in: PubMed
    Score: 0.148
  30. Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr Oncol Rep. 2013 Oct; 15(5):483-91.
    View in: PubMed
    Score: 0.139
  31. Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect. Nat Rev Clin Oncol. 2012 Sep; 9(9):496-7.
    View in: PubMed
    Score: 0.129
  32. A potential role for nilotinib in KIT-mutated melanoma. Expert Opin Investig Drugs. 2012 Jun; 21(6):861-9.
    View in: PubMed
    Score: 0.126
  33. Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol. 2010 Apr; 8(4):259-66.
    View in: PubMed
    Score: 0.109
  34. Management of metastatic melanoma. Semin Oncol. 2007 Dec; 34(6):532-45.
    View in: PubMed
    Score: 0.093
  35. The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy. Semin Oncol Nurs. 2024 Feb; 40(1):151574.
    View in: PubMed
    Score: 0.071
  36. Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. Immunotherapy. 2024 Jan; 16(1):29-42.
    View in: PubMed
    Score: 0.070
  37. Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol. 2023 10 01; 159(10):1076-1084.
    View in: PubMed
    Score: 0.070
  38. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer. 2023 10; 11(10).
    View in: PubMed
    Score: 0.070
  39. Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. Neuro Oncol. 2023 Jul 06; 25(7):1310-1320.
    View in: PubMed
    Score: 0.069
  40. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med. 2023 Jun; 29(6):1310-1312.
    View in: PubMed
    Score: 0.068
  41. The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022. J Transl Med. 2023 04 18; 21(1):265.
    View in: PubMed
    Score: 0.068
  42. Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO Precis Oncol. 2023 04; 7:e2200421.
    View in: PubMed
    Score: 0.067
  43. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.
    View in: PubMed
    Score: 0.067
  44. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. Eur J Cancer. 2023 07; 187:164-173.
    View in: PubMed
    Score: 0.067
  45. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. J Clin Oncol. 2023 05 20; 41(15):2724-2735.
    View in: PubMed
    Score: 0.067
  46. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clin Cancer Res. 2023 02 01; 29(3):521-531.
    View in: PubMed
    Score: 0.067
  47. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
    View in: PubMed
    Score: 0.065
  48. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2022 11; 35(6):554-572.
    View in: PubMed
    Score: 0.065
  49. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
    View in: PubMed
    Score: 0.064
  50. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. J Transl Med. 2022 05 10; 20(1):200.
    View in: PubMed
    Score: 0.063
  51. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022 05 02; 28(9):1911-1924.
    View in: PubMed
    Score: 0.063
  52. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Jun; 29(6):3694-3708.
    View in: PubMed
    Score: 0.062
  53. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. J Clin Oncol. 2022 05 01; 40(13):1428-1438.
    View in: PubMed
    Score: 0.062
  54. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 01 06; 386(1):24-34.
    View in: PubMed
    Score: 0.062
  55. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer. 2022 01; 10(1).
    View in: PubMed
    Score: 0.062
  56. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
    View in: PubMed
    Score: 0.062
  57. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
    View in: PubMed
    Score: 0.061
  58. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer. 2022 03 01; 128(5):975-983.
    View in: PubMed
    Score: 0.061
  59. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021 11; 9(11).
    View in: PubMed
    Score: 0.061
  60. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.059
  61. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med. 2021 04 07; 19(1):142.
    View in: PubMed
    Score: 0.059
  62. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021 03 26; 10(1):1898105.
    View in: PubMed
    Score: 0.059
  63. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med. 2021 04; 10(7):2293-2299.
    View in: PubMed
    Score: 0.058
  64. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021 02; 27(2):301-309.
    View in: PubMed
    Score: 0.058
  65. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697.
    View in: PubMed
    Score: 0.058
  66. Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma. Acta Derm Venereol. 2020 Nov 26; 100(18):adv00334.
    View in: PubMed
    Score: 0.057
  67. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.
    View in: PubMed
    Score: 0.057
  68. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020 10; 26(10):1557-1563.
    View in: PubMed
    Score: 0.057
  69. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895.
    View in: PubMed
    Score: 0.054
  70. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
    View in: PubMed
    Score: 0.054
  71. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell Melanoma Res. 2020 07; 33(4):527-541.
    View in: PubMed
    Score: 0.054
  72. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
    View in: PubMed
    Score: 0.054
  73. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer. 2019 Dec 01; 125(23):4193-4202.
    View in: PubMed
    Score: 0.052
  74. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K? Inhibition in PTEN Loss Melanoma. Clin Cancer Res. 2019 11 01; 25(21):6406-6416.
    View in: PubMed
    Score: 0.052
  75. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.
    View in: PubMed
    Score: 0.052
  76. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019 06; 25(6):929-935.
    View in: PubMed
    Score: 0.052
  77. The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018. J Transl Med. 2019 05 10; 17(1):148.
    View in: PubMed
    Score: 0.051
  78. Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
    View in: PubMed
    Score: 0.051
  79. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol. 2019 May; 142(3):499-509.
    View in: PubMed
    Score: 0.051
  80. Reply to A. Shinde et al. J Clin Oncol. 2019 04 20; 37(12):1031-1032.
    View in: PubMed
    Score: 0.051
  81. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
    View in: PubMed
    Score: 0.051
  82. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2019 05; 32(3):458-469.
    View in: PubMed
    Score: 0.051
  83. Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 11 29; 379(22):2178.
    View in: PubMed
    Score: 0.050
  84. NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
    View in: PubMed
    Score: 0.049
  85. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.049
  86. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.048
  87. Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol. 2018 Jul; 45(7):545-549.
    View in: PubMed
    Score: 0.048
  88. Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila). 2018 07; 11(7):429-438.
    View in: PubMed
    Score: 0.048
  89. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.047
  90. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res. 2017 12; 27(6):585-590.
    View in: PubMed
    Score: 0.047
  91. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neurooncol. 2017 Jul; 133(3):595-602.
    View in: PubMed
    Score: 0.045
  92. Melanoma Brain Metastases: Current Areas of Investigation and Future Directions. Cancer J. 2017 Jan/Feb; 23(1):68-74.
    View in: PubMed
    Score: 0.044
  93. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar; 5(3):264-73.
    View in: PubMed
    Score: 0.038
  94. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
    View in: PubMed
    Score: 0.036
  95. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15; 74(4):1045-55.
    View in: PubMed
    Score: 0.035
  96. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95.
    View in: PubMed
    Score: 0.033
  97. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20; 30(3):322-8.
    View in: PubMed
    Score: 0.031
  98. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer. 2008 Mar 01; 112(5):1131-8.
    View in: PubMed
    Score: 0.024
  99. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.015
  100. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res. 2017 05; 30(3):328-338.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.